Antimetabolites in the management of non-small cell lung cancer

Leanne S. Budde, Nasser Hanna

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Non-small cell lung cancer (NSCLC) is the leading cause of cancer-related death in the United States. Although chemotherapy has been shown to increase survival for patients with advanced-stage disease, survival benefits have been modest and come at the cost of significant toxicity. Treatment options in the second-line setting have been limited. Pemetrexed, a multitargeted antifolate, has activity as a single agent and as part of combination chemotherapy against NSCLC. As reported in a recent phase III clinical trial, survival outcomes in the second-line setting for patients treated with pemetrexed or docetaxel are similar. More importantly, major toxicity with the use of pemetrexed with vitamin B12 and folate supplementation is far less than with docetaxel. Based on its single agent activity, ease of administration, and favorable toxicity profile, pemetrexed has the potential to be incorporated in various settings against NSCLC, including metastatic disease, as adjuvant therapy, and for locally advanced disease.

Original languageEnglish (US)
Pages (from-to)83-93
Number of pages11
JournalCurrent Treatment Options in Oncology
Volume6
Issue number1
StatePublished - Jan 2005
Externally publishedYes

Fingerprint

Pemetrexed
Antimetabolites
docetaxel
Non-Small Cell Lung Carcinoma
Survival
Folic Acid Antagonists
Phase III Clinical Trials
Vitamin B 12
Combination Drug Therapy
Folic Acid
Drug Therapy
Therapeutics
Neoplasms

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Antimetabolites in the management of non-small cell lung cancer. / Budde, Leanne S.; Hanna, Nasser.

In: Current Treatment Options in Oncology, Vol. 6, No. 1, 01.2005, p. 83-93.

Research output: Contribution to journalArticle

@article{00207adf9ef941d7bcde4fb1bfc4fab5,
title = "Antimetabolites in the management of non-small cell lung cancer",
abstract = "Non-small cell lung cancer (NSCLC) is the leading cause of cancer-related death in the United States. Although chemotherapy has been shown to increase survival for patients with advanced-stage disease, survival benefits have been modest and come at the cost of significant toxicity. Treatment options in the second-line setting have been limited. Pemetrexed, a multitargeted antifolate, has activity as a single agent and as part of combination chemotherapy against NSCLC. As reported in a recent phase III clinical trial, survival outcomes in the second-line setting for patients treated with pemetrexed or docetaxel are similar. More importantly, major toxicity with the use of pemetrexed with vitamin B12 and folate supplementation is far less than with docetaxel. Based on its single agent activity, ease of administration, and favorable toxicity profile, pemetrexed has the potential to be incorporated in various settings against NSCLC, including metastatic disease, as adjuvant therapy, and for locally advanced disease.",
author = "Budde, {Leanne S.} and Nasser Hanna",
year = "2005",
month = "1",
language = "English (US)",
volume = "6",
pages = "83--93",
journal = "Current Treatment Options in Oncology",
issn = "1527-2729",
publisher = "Springer New York",
number = "1",

}

TY - JOUR

T1 - Antimetabolites in the management of non-small cell lung cancer

AU - Budde, Leanne S.

AU - Hanna, Nasser

PY - 2005/1

Y1 - 2005/1

N2 - Non-small cell lung cancer (NSCLC) is the leading cause of cancer-related death in the United States. Although chemotherapy has been shown to increase survival for patients with advanced-stage disease, survival benefits have been modest and come at the cost of significant toxicity. Treatment options in the second-line setting have been limited. Pemetrexed, a multitargeted antifolate, has activity as a single agent and as part of combination chemotherapy against NSCLC. As reported in a recent phase III clinical trial, survival outcomes in the second-line setting for patients treated with pemetrexed or docetaxel are similar. More importantly, major toxicity with the use of pemetrexed with vitamin B12 and folate supplementation is far less than with docetaxel. Based on its single agent activity, ease of administration, and favorable toxicity profile, pemetrexed has the potential to be incorporated in various settings against NSCLC, including metastatic disease, as adjuvant therapy, and for locally advanced disease.

AB - Non-small cell lung cancer (NSCLC) is the leading cause of cancer-related death in the United States. Although chemotherapy has been shown to increase survival for patients with advanced-stage disease, survival benefits have been modest and come at the cost of significant toxicity. Treatment options in the second-line setting have been limited. Pemetrexed, a multitargeted antifolate, has activity as a single agent and as part of combination chemotherapy against NSCLC. As reported in a recent phase III clinical trial, survival outcomes in the second-line setting for patients treated with pemetrexed or docetaxel are similar. More importantly, major toxicity with the use of pemetrexed with vitamin B12 and folate supplementation is far less than with docetaxel. Based on its single agent activity, ease of administration, and favorable toxicity profile, pemetrexed has the potential to be incorporated in various settings against NSCLC, including metastatic disease, as adjuvant therapy, and for locally advanced disease.

UR - http://www.scopus.com/inward/record.url?scp=13544270238&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=13544270238&partnerID=8YFLogxK

M3 - Article

VL - 6

SP - 83

EP - 93

JO - Current Treatment Options in Oncology

JF - Current Treatment Options in Oncology

SN - 1527-2729

IS - 1

ER -